Related Experiment Video
Updated: Jun 25, 2025
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
2.7K
Neuroinflammation and Dyskinesia: A Possible Causative Relationship?
Antonella Cardinale1,2, Antonio de Iure1,2, Barbara Picconi1,2
1Experimental Neurophysiology Laboratory, IRCCS San Raffaele Roma, 00166 Rome, Italy.
Brain Sciences
|May 25, 2024
Summary
Levodopa (L-DOPA) treatment for Parkinson's disease causes side effects like L-DOPA-induced dyskinesias (LIDs). Neuroinflammation involving microglia and astrocytes plays a key role in LIDs development, suggesting new therapeutic targets.
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Levodopa (L-DOPA) is the primary treatment for Parkinson's disease (PD).
- L-DOPA-induced dyskinesias (LIDs) are a significant side effect of L-DOPA therapy.
- Mechanisms of LIDs involve neuronal and non-neuronal pathways, including neuroinflammation.
Purpose of the Study:
- To review the contribution of neuroinflammation to LIDs.
- To explore the role of glial cells (microglia and astrocytes) in LIDs.
- To identify potential therapeutic strategies targeting glia for LIDs prevention.
Main Methods:
- Systematic review of clinical and pre-clinical studies.
- Analysis of research on neuroinflammation and LIDs.
- Examination of glial cell involvement in LIDs pathogenesis.
Main Results:
- Neuroinflammation, particularly involving microglia and astrocytes, is implicated in LIDs.
- Glial inflammatory responses impact neuron-glia communication, synaptic activity, and neuroplasticity.
- These inflammatory processes contribute to the development of LIDs.
Conclusions:
- Glial cells play a critical role in the development of LIDs.
- Targeting glial inflammatory pathways offers a promising therapeutic avenue for preventing LIDs.
- Future research should focus on developing glia-centric interventions for PD patients.
Related Concept Videos
01:15Parkinson's Disease: Overview
528
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
528
01:37Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
01:24Parkinson's Disease: Treatment
261
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
261
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
309
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
309
01:29Excitatory and Inhibitory Effects of Neurotransmitters
9.9K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
9.9K